The BEAR Implant for ACL Tears: What My Patients Should Know
The BEAR implant repairs your own ACL instead of replacing it. What the newest registry data shows about re-tear rates, the FDA arthritis label, and who is a good candidate.
If you tear your ACL, the standard treatment has been the same for decades: we take a tendon from somewhere else in your body (or from a donor) and use it to rebuild the ligament from scratch. It works well — I perform approximately 85 ACL reconstructions a year, and the vast majority of my patients get back to the activities they love.
But a newer option called the BEAR Implant (Bridge-Enhanced ACL Restoration) has been generating a lot of buzz, and I get asked about it in clinic almost every week. The data on it has also shifted meaningfully in the past year. So let's talk about what it actually is, what the research shows now, and who might be a good candidate.
What is the BEAR Implant?
Instead of replacing your torn ACL with a graft, the BEAR procedure uses a small sponge-like implant made of bovine collagen that's injected with a sample of your own blood and placed between the torn ends of your ACL. The idea is that the implant acts as a scaffold, encouraging your body's own healing response to repair the native ligament rather than replacing it entirely. The implant dissolves over about eight weeks as your ligament heals around it.
It's an appealing concept: keep your own ACL, avoid harvesting a tendon from your knee or hamstring, and potentially preserve the native nerve fibers and proprioception in the ligament.
The procedure received FDA clearance in 2020 and is indicated for midsubstance or proximal ACL tears in patients 14 and older who have enough remaining ACL tissue (a "stump") for the implant to bridge. Since then, surgeons have also refined how the torn ligament is stitched and anchored to the bone before the implant is placed — and, as you'll see below, that seems to matter.
What the research actually shows
Here's where I want to be straightforward with you, because this is a topic where the marketing can get ahead of the science, and where the science itself has been moving quickly.
The good news on arthritis
In early 2026 the FDA updated the BEAR Implant's label to include a claim that it may reduce the risk of developing post-traumatic osteoarthritis compared to hamstring autograft ACL reconstruction.1 That's meaningful. Post-traumatic arthritis after an ACL tear is something I counsel every patient about, and anything that lowers that risk is worth paying attention to. Six-year follow-up from the first-in-human study has also shown similar patient-reported outcomes between BEAR and standard reconstruction.2
The original concern
Across the first three BEAR clinical trials, the aggregate re-tear rate was about 15%, compared to roughly 6% for traditional ACL reconstruction with autograft.3,4 That's more than double, and it was the main reason I stayed cautious. A re-tear means another surgery, more time off work and sports, and starting rehab over from zero.
What's changed
Once the implant went into wider use, a multicenter registry (the Bridge Registry, nine sites, 300 patients) began tracking real-world results, and the numbers look different from the original trials. In the first 100 patients, published this year, the ACL re-tear rate was about 2% at an average of 15 months and roughly 5% at two years.5 Broken out by age, that was about 4% in adults and 8% in athletes under 18, with most of the teenage re-tears happening during sports.
In July 2026, at the sports medicine meeting held here in Seattle, the group presented two-year data on the first 200 patients, and the re-tear rate was still tracking around 5%, which is squarely in the range we see with standard reconstruction.6 Notably, half of those cases used a modified technique in which the torn ligament is stitched and anchored directly to the femur with a button or suture anchor before the implant goes in, and that modified approach had a lower reoperation rate than the original method.7
The grain of salt
Registry data is encouraging, but it isn't the same as a randomized trial. The registry is sponsored by the implant's manufacturer, the surgeons chose which patients got BEAR, and two years is still early for an ACL.
A separate 2026 series from another academic center, comparing BEAR to patellar tendon and quad tendon reconstruction, found BEAR's failure rate was still roughly double, even in patients with favorable tear patterns (though the difference wasn't statistically significant and BEAR had fewer other complications).8 The study that will really settle this is BEAR-MOON, a randomized trial comparing BEAR head-to-head against patellar tendon reconstruction. It finished enrolling in 2025, and results are still a year or two away.9
| Factor | BEAR Implant | ACL reconstruction (autograft) |
|---|---|---|
| What happens | Native ACL is repaired with a collagen scaffold | Torn ACL replaced with a tendon graft |
| Re-tear rate | ~15% in original trials; ~5% at 2 years in newer registry data with refined technique | ~6% (autograft) |
| Graft / donor site needed | No | Yes (hamstring, patellar tendon, or quad) |
| Post-traumatic arthritis risk | Potentially lower (FDA label claim) | Standard baseline |
| Long-term data available | 6 years (small cohort); 2 years in a few hundred registry patients | 30+ years, thousands of patients |
| Tear location requirement | Midsubstance or proximal, with enough stump to repair | Any tear pattern |
My honest take
I think the BEAR Implant is a genuinely exciting development in ACL treatment, and the past year has moved me. The osteoarthritis data was already encouraging; the newer registry numbers suggest that with careful patient selection and a refined technique, the re-tear rate may be much closer to standard reconstruction than the original trials implied.
That said, I'm not ready to make it my default for everyone. The best evidence we have is still non-randomized, the head-to-head trial against patellar tendon graft isn't out yet, and the 8% re-tear rate in teenage athletes is a reminder that a repaired ligament is being asked to do a hard job.
The group of patients for whom I think BEAR is a real option, though, has grown: someone with a proximal or midsubstance tear with a healthy stump, seen within the first couple of months after injury, who wants to avoid a graft harvest. It's a conversation I'm happy to have in clinic. But the answer to "should I get the BEAR instead of a regular ACL reconstruction?" is still: it depends, and we'll figure it out together based on your tear pattern, activity goals, and what matters most to you.
If you've torn your ACL and you're wondering whether the BEAR Implant might be right for you, I'd love to talk it through. Every knee is different, and my job is to help you understand all your options so you can make the best decision for your life and your goals.
References
- Miach Orthopaedics. FDA approves updated label for BEAR Implant to include significantly lower risk of osteoarthritis [press release]. Business Wire. businesswire.com/news/home/20260114688148/en/
- Fleming BC, Baranker B, Badger GJ, et al. Bridge-enhanced anterior cruciate ligament restoration: 6-year results from the first-in-human cohort study. Orthop J Sports Med. 2024;12(8):23259671241260632. doi:10.1177/23259671241260632
- Murray MM, Fleming BC, Badger GJ, et al; BEAR Trial Team. Bridge-enhanced anterior cruciate ligament repair is not inferior to autograft anterior cruciate ligament reconstruction at 2 years: results of a prospective randomized clinical trial. Am J Sports Med. 2020;48(6):1305-1315. doi:10.1177/0363546520913532
- Shah AK, Neijna AG, Retzky JS, Gomoll AH, Strickland SM. Indications, techniques, and outcomes of bridge-enhanced ACL restoration (BEAR). Curr Rev Musculoskelet Med. 2025;18(4):140-148. doi:10.1007/s12178-025-09950-1
- Wittstein J, Strickland S, Gomoll A, et al. Postcommercialisation outcomes of bridge-enhanced anterior cruciate ligament restoration: the first 100 Bridge registry patients. Knee Surg Sports Traumatol Arthrosc. 2026;34(6):2013-2024. doi:10.1002/ksa.12806
- Miach Orthopaedics. BEAR Implant registry data demonstrate low ACL retear rates with evolved surgical techniques [press release]. Business Wire. July 8, 2026. Presented at the AOSSM Annual Meeting, Seattle, WA.
- Lorentz SG, Aman ZS, Lau BC, Wittstein JR, Brady JM. Various technique modifications of BEAR ACL restoration. Video J Sports Med. 2026;6(3). doi:10.1177/26350254261419142
- Bridge-enhanced ACL repair may have higher failure rates vs. ACL reconstruction. Healio Orthopedics. March 25, 2026. Presented at the AAOS Annual Meeting, 2026.
- A comparison of ACL repair with BEAR device vs. autograft patellar tendon ACL reconstruction (BEAR-MOON). ClinicalTrials.gov identifier NCT03776162.
This article is general education, not medical advice for your situation. Every knee and hip is different — talk with your own doctor about your care.